Novartis AG ADR (NVS)vsPennant Group Inc (PNTG)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
PNTG
Pennant Group Inc
$39.20
-0.25%
HEALTHCARE · Cap: $1.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5046% more annual revenue ($56.69B vs $1.10B). NVS leads profitability with a 22.5% profit margin vs 2.9%. PNTG appears more attractively valued with a PEG of 1.90. PNTG earns a higher WallStSmart Score of 59/100 (C).
NVS
Buy51
out of 100
Grade: C-
PNTG
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for PNTG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 35.8% year-over-year
Earnings expanding 25.0% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Distress zone — elevated risk
Smaller company, higher risk/reward
2.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PNTG
The strongest argument for PNTG centers on Revenue Growth, EPS Growth. Revenue growth of 35.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PNTG
The primary concerns for PNTG are PEG Ratio, Altman Z-Score, Market Cap. A P/E of 42.2x leaves little room for execution misses. Thin 2.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while PNTG is a hypergrowth play — different risk/reward profiles.
PNTG carries more volatility with a beta of 1.27 — expect wider price swings.
PNTG is growing revenue faster at 35.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PNTG scores higher overall (59/100 vs 51/100) and 35.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Pennant Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Pennant Group, Inc. provides health care services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company is headquartered in Eagle, Idaho.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?